1.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

2.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

3.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

4.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

5.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

6.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

7.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

8.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

9.

Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results.

1.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

2.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

3.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

4.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

5.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

6.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

7.

Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.

1.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

2.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

3.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

4.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

5.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

6.

Effect of hospital volume on quality of care and outcome after rectal cancer surgery.

1.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

2.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

3.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

4.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

5.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

6.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

7.

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis.

1.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

2.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

3.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

4.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

5.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

6.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

7.

Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety.

1.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

2.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

3.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

4.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

5.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

6.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

7.

Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.

1.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

2.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

3.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

4.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

5.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

6.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

7.

Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes.

1.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

2.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

3.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

4.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

5.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

6.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

7.

Myocardial Contraction Fraction for Risk Stratification in Low-Gradient Aortic Stenosis With Preserved Ejection Fraction.

1.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

2.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

3.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

4.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

5.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

6.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

7.

Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia.

1.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

2.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

3.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

4.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

5.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

6.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

7.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

8.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

9.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.